Ocuphire Eyes Phase III Path For APX3330 After Mixed Trial Results

The diabetic retinopathy candidate failed on its Phase II primary endpoint, but showed efficacy on a key secondary endpoint that the company hopes to use as the Phase III primary outcome measure.

Ocuphire announed topline results from its Phase II ZETA-1 trial • Source: Shutterstock

One road ahead for Ocuphire Pharma, Inc.’s oral diabetic retinopathy drug APX3330 may have closed as it failed to meet the primary endpoint in a Phase II clinical trial, but the company is counting on another path remaining open as the study’s results showed efficacy for the drug on other clinically meaningful endpoints.

Without releasing detailed results, Ocuphire announced top-line results on 25 January from the Phase II ZETA-1 trial comparing APX3330 against placebo in 103 patients with diabetic retinopathy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.